Venn Life Sciences Announce Partnership

Venn Life Sciences Holdings Plc
(“Venn” or the “Company”)

Partnership Announcement

Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces its partnership with Carrick Therapeutics Ltd (“Carrick Therapeutics”).

Venn Life Sciences announce partnership

Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer and are optimised to a patient’s individual tumour through identification of predictive biomarkers. Carrick Therapeutics has built a network of partners and collaborators to progress its technology portfolio and Venn is delighted to join this network as a provider of Early Development and Clinical Research capabilities.

About Carrick Therapeutics:

Carrick Therapeutics has a clear vision for cancer patients: to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Whilst other companies bank on a single compound or biological mechanism, Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance, allied with cutting-edge technologies to identify therapeutics and those who would most benefit from them.

Commenting on this development, Tony Richardson CEO of Venn Life Sciences stated;

In so many respects Carrick Therapeutics represents the model client for Venn. Highly innovative with a portfolio approach focusing on their core IP while working on an outsource basis with a well-developed network of support partners. At Venn we have built a suite of capabilities designed to address all of the development requirements of this model and are delighted to partner with Carrick in the development of their first in class treatments.”

Commenting on this development, Elaine Sullivan CEO of Carrick Therapeutics stated;

By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, we will use our multi-asset portfolio to drive the development of these ground-breaking cancer therapies from laboratory to clinic. Together with our academic and biotech partners, we are looking to detect predictive biomarkers in each of our projects to enable us to identify those who would benefit most from our therapies. These targeted treatments will bring a higher quality of life to cancer patients around the world. We are partnering with Venn to provide development and clinical capabilities and they are a welcome addition to our network.

Enquiries:

Venn Life Sciences Holdings Plc  Tel: +353 1 5499 341
Tony Richardson, Chief Executive Officer

Cenkos (Nominated Advisor and Co-Broker)  Tel: +44 (0)20 7397 8900
Mark Connelly / Steve Cox (Corporate Finance)

Davy (ESM Adviser and Co-Broker)  Tel: +353 (0)1 679 6363
Fergal Meegan / Matthew de Vere White (Corporate Finance)

About Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com
Venn life Sciences: getintouch@vennlife.com
Carrick Therapeutic: elaine.sullivan@carricktherapeutics.com